Testing HRS-1738 for imaging prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This study tests a new diagnostic drug called HRS-1738 to see if it can help detect prostate cancer more clearly on PET/CT scans. If you have prostate cancer that has been confirmed by a biopsy and you are in fairly good health, this trial may help improve how your cancer is seen and monitored.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a man aged 18 or older.
- You must have prostate adenocarcinoma (a common type of prostate cancer) confirmed by a biopsy or tissue sample.
- You should be able to take care of yourself (ECOG score 0 or 1).
- If you have had surgery for prostate cancer, it must have been at least 8 to 12 weeks ago, and you must have recovered well.
- You cannot have serious medical issues like uncontrolled diabetes, heart disease, active infections (like hepatitis B or C, HIV, or syphilis), or other cancers that haven't been cured.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new radioactive tracer that may help doctors see and treat prostate cancer that has spread. The tracer attaches to cancer cells so they show up on scans, and may also help guide treatment.
This study tests a new imaging drug called Flotufolastat F-18 to find prostate cancer that has returned after treatment. The goal is to see how well and safely it finds the cancer spots, which could help guide next steps.
This study tests a new imaging agent (68Ga-NYM032) used with PET/CT scans to help doctors better detect prostate cancer before surgery. If you have biopsy-confirmed prostate cancer and are planning to have your prostate removed, this trial may help evaluate whether this new imaging method improves cancer detection.
This study tests a new type of PET scan (a detailed imaging test) to find out if prostate cancer has come back after treatment. You'll receive an injection of a special tracer and then have a scan that takes pictures to help doctors locate any cancer.
This trial tests a new type of PET scan to see how well it finds leftover cancer after you've had focal therapy (treatment to just part of the prostate) for intermediate-risk prostate cancer in the last 9 months.
This study tests a new type of PET/CT scan that uses a special tracer (68Ga-MY6349) to better see prostate cancer in the body. It may help doctors find cancer that has come back or spread, so you can get the right treatment sooner.
Hear when a new PET Imaging in Patients With Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.